NDC-11 (Package) | NDC-9 (Product) | Generic Name (Ascending) | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00703-4075-51 | 00703-4075 | Pamidronate Disodium | Pamidronate Disodium | 3.0 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | Nov. 8, 2005 | Nov. 8, 2005 | In Use | |
00703-4085-51 | 00703-4085 | Pamidronate Disodium | Pamidronate Disodium | 9.0 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | Nov. 8, 2005 | Sept. 30, 2012 | In Use | |
63323-0735-10 | 63323-0735 | Pamidronate Disodium | Pamidronate Disodium | 9.0 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | May 19, 2002 | Aug. 27, 2015 | In Use | |
67457-0472-10 | 67457-0472 | Pamidronate Disodium | Pamidronate Disodium | 3.0 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | May 10, 2011 | Nov. 30, 2018 | No Longer Used | |
55513-0954-01 | 55513-0954 | Panitumumab | Vectibix | 100.0 mg/5mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Oct. 10, 2006 | In Use | |
55513-0956-01 | 55513-0956 | Panitumumab | Vectibix | 400.0 mg/20mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Oct. 10, 2006 | In Use | |
55513-0955-01 | 55513-0955 | Panitumumab | Vectibix | 200.0 mg/10mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Oct. 10, 2006 | Feb. 28, 2010 | No Longer Used |
00078-0651-06 | 00078-0651 | Panobinostat | Farydak | 15.0 mg/1 | Chemotherapy | Enzyme Inhibitor | HDAC | Oral | Feb. 23, 2015 | Dec. 31, 2022 | No Longer Used |
00078-0652-06 | 00078-0652 | Panobinostat | Farydak | 20.0 mg/1 | Chemotherapy | Enzyme Inhibitor | HDAC | Oral | Feb. 23, 2015 | Dec. 31, 2022 | No Longer Used |
00078-0650-06 | 00078-0650 | Panobinostat | Farydak | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | HDAC | Oral | Feb. 23, 2015 | Jan. 31, 2023 | No Longer Used |
Found 10,000 results in 8 milliseconds — Export these results